Valuation: Verastem, Inc.

Market Cap 592M 512M 478M 439M 825M 56.37B 839M 5.61B 2.2B 28.25B 2.22B 2.18B 93.4B P/E 2026 *
-4.29x
P/E 2027 * -5.91x
Enterprise Value 634M 549M 512M 470M 884M 60.35B 898M 6.01B 2.36B 30.25B 2.38B 2.33B 100B EV / Sales 2026 *
5.73x
EV / Sales 2027 * 2.1x
Free-Float
96.13%
Yield 2026 *
-
Yield 2027 * -
1 day+14.04%
1 week+16.21%
Current month+16.21%
1 month+32.68%
3 months+37.83%
6 months+1.05%
Current year-12.69%
1 week 5.58
Extreme 5.58
7.1
1 month 5.06
Extreme 5.0595
7.1
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0017%
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+14.04%+16.21%0.00%-32.80% 592M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +4.86%+12.14%+48.60%+183.58% 26.42B
Weighted average by Cap. +4.38%+13.10%+50.58%+168.02%

Financials

2026 *2027 *
Net sales 111M 95.81M 89.47M 82.08M 154M 10.54B 157M 1.05B 412M 5.28B 416M 407M 17.47B 183M 158M 147M 135M 254M 17.38B 258M 1.73B 679M 8.71B 686M 671M 28.79B
Net income -163M -141M -132M -121M -228M -15.54B -231M -1.55B -607M -7.79B -613M -600M -25.75B -144M -125M -117M -107M -201M -13.74B -204M -1.37B -537M -6.89B -542M -530M -22.77B
Net Debt 41.9M 36.24M 33.85M 31.05M 58.4M 3.99B 59.33M 397M 156M 2B 157M 154M 6.61B -210M -181M -169M -155M -292M -19.95B -297M -1.99B -780M -10B -787M -770M -33.05B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
07/08/26 US$6.740 +14.04% 4,319,009
06/08/26 US$5.910 +0.68% 2,189,459
05/08/26 US$5.870 +1.03% 1,554,979
04/08/26 US$5.810 +2.11% 1,791,796
03/08/26 US$5.690 -1.90% 1,288,075
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.740USD
Average target price
14.88USD
Spread / Average Target
+120.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock